Tampa, FL (Oct. 26, 2021) --A screening blood test originally validated in seriously ill patients without COVID-19 is still clinically useful for ruling out pulmonary embolism in patients hospitalized ...

Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients. Background: Procoagulant changes in the haemostatic system and activation of ...

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading across many parts of the world, and clinicians are working on recognizing biomarkers ...

Does an elevated ultrasensitive D-dimer level in a patient whose pre-test probability puts him at low risk for pulmonary embolus (PE) indicate an increased risk for PE or deep venous thrombosis (DVT)?